Skip to main content
. 2017 Sep 21;25(8):1341–1348. doi: 10.3727/096504017X14867268787969

Figure 1.

Figure 1

Expression of miR-181a in cervical cancer cell lines. (A) The miR-181a expression level of four cervical cancer cell lines (HeLa, SiHa, C-33A, and HT-3) was evaluated by qRT-PCR. The miR-181a expressions of the four cervical cancer cell lines were significantly different. (B) The BrdU incorporation was measured by enzyme-linked immunosorbent assay (ELISA). The difference of the BrdU incorporations between the four cervical cancer cell lines was also significant. (C) Response to the oxaliplatin (OXA) treatment was evaluated by cell viability. A significant difference was observed among the mean viabilities of each cell lines. NS, nonsignificant. *p < 0.05; **p < 0.01; ***p < 0.001.